Sankala Group’s Pfizer PFE Stock Holding History

Sankala Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$977	Hold	36	–	–	﹤0.01%	550
2026 Q1	$981	Hold	36	–	–	﹤0.01%	526
2025 Q4	$990	Buy	+36	New	+$908	﹤0.01%	541

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sankala Group's PFE Position: Q2 2026 in Review

Sankala Group held its Pfizer (PFE) position steady in Q2 2026 at 36 shares worth $977. The position accounts for ﹤0.01% of the portfolio, ranked #550.

Sankala Group first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $990 in Q4 2025. 2,839 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Sankala Group held 36 shares of Pfizer worth $977 as of Q2 2026.
Sankala Group left its Pfizer share count unchanged in Q2 2026.
Pfizer made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #550 holding.
Sankala Group first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
Sankala Group's Pfizer position peaked at $990 in Q4 2025.
2,839 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.